Switch to:
More From Other Websites
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog Apr 17 2015
Pfizer Wins First Trial Over Zoloft Birth-Defect Claims Apr 17 2015
Pfizer wins first U.S. trial over Zoloft birth-defect risk Apr 17 2015
Teva Getting Serious About Mylan Bid, Says Report Apr 17 2015
Pfizer Jury Told Zoloft Risks Known But Hidden From Patients Apr 17 2015
A Beginner's Guide to Pharma ETFs - ETF News And Commentary Apr 17 2015
Dorset Management Made a Bundle By Betting on Biotech and Energy; More Profits to Come? Apr 17 2015
Why Supposedly Abuse-Proof Pills Won't Stop Opioid Overdose Deaths Apr 17 2015
Maverick Capital Increases Stake in Novartis Apr 17 2015
The 5 Best DJIA Stocks of 2015 — With More Upside Expected Apr 17 2015
AstraZeneca lung cancer drug delays disease by more than a year Apr 17 2015
Is This Pfizer's Next Mega-Blockbuster Drug? Apr 16 2015
Biotech giants present new data Apr 16 2015
Pfizer's Ibrance Study Stopped Early on Favorable Data - Analyst Blog Apr 16 2015
Antitrust Protections Hardly Provide a 'Road Map' for Merger Challenges, Regulators Say Apr 16 2015
Big pharma M&A may keep booming, CEOs say Apr 16 2015
Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders Apr 16 2015
Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders Apr 16 2015
Boston Business Journal's 2015 Pacesetters celebrates the region's fastest-growing companies (photo... Apr 16 2015
Need to change the laws on corporate tax: Pfizer CEO Apr 16 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

SEENSCO
ReplySEENSCO - 10 months ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK